Neovasc Inc.
https://www.neovasc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neovasc Inc.
Abbott And Coroventis Partner To Address Often-Overlooked Microvascular Dysfunction
Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.
FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.
Feasibility Trial Of Medtronic’s Intrepid Transfemoral TMVR Begins
A new trial will evaluate the feasibility of implanting Medtronic's Intrepid transcatheter mitral valve replacement system through a transfemoral approach after the Intrepid TMVR study showed the feasibility of implanting Intrepid through the transapical approach.
Starts & Stops: Neovasc Reports Progress On TIARA-II Trial Of Transcatheter Mitral Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive